Home > Press > Transfer of Intellectual Property, Patents and Technology to FutureCarbon: Bayer sells patents for carbon nanotubes and graphenes
Abstract:
After concluding its research work on carbon nanotubes (CNT) and graphenes, Bayer MaterialScience is divesting itself of fundamental intellectual property in this field. The company FutureCarbon GmbH, based in Bayreuth, Germany, will acquire, as leading provider of carbon-based composites, the bulk of the corresponding patents from the past ten years. The two parties have now signed an agreement to this effect. The financial details of the transfer will not be disclosed.
"We are pleased that FutureCarbon, one of the partners from the Inno.CNT development network, will be carrying on our company's work," said Patrick Thomas, CEO of Bayer Material Science. "We remain confident that the technology harbors tremendous potential, particularly for a renowned specialist company like FutureCarbon."
FutureCarbon GmbH is a leading innovator and provider of novel, carbon-based composites. As a specialist in the manufacture and in particular the refinement of various carbon materials, FutureCarbon enables a broad range of strategic industries, to easily utilize the extraordinary properties of carbon materials in their products.
"We enjoy a long-standing development partnership with Bayer. We are happy that we were able to acquire the Bayer patents for further market realization of the technology. They expand our applications base substantially and open up new possibilities and business segments for us," said Dr. Walter Schütz, managing director of the Bayreuth company.
Researchers from Bayer MaterialScience had conducted substantial research and development work in the field of carbon nanotubes in collaboration with external partners in recent years. This included complex issues relating to safe production and methods for scaling up the production processes. Next-generation catalysts and new product grades were also developed.
Much of the knowledge gleaned over recent years was made available to other companies and research institutions within the Innovation Alliance for Carbon Nanotubes (Inno.CNT), which counts Bayer MaterialScience among its roughly 90 members.
After Bayer MaterialScience announced the conclusion of its CNT projects in May 2013, various companies indicated their interest in making concrete use of intellectual property developed before the decision was made for FutureCarbon as ideal partner for taking over the accomplished knowledge.
####
About Bayer MaterialScience
With 2013 sales of EUR 11.2 billion, Bayer MaterialScience is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. At the end of 2013, Bayer MaterialScience had 30 production sites and employed approximately 14,300 people around the globe. Bayer MaterialScience is a Bayer Group company.
About FutureCarbon GmbH
FutureCarbon specializes in the development and manufacture of carbon nanomaterials and their refinement to create what are called carbon supercomposites, primary products for further industrial processing. Carbon supercomposites are combinations of materials that unfold the special characteristics of carbon nano-materials in the macroscopic world of real applications. All of our materials are manufactured on an industrial scale.
www.future-carbon.de
This news release is available for download from the Bayer MaterialScience press server at www.press.bayerbms.com.
Find more information at www.materialscience.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For more information, please click here
Contacts:
Stefan Paul Mechnig
Tel. +49 214 30-36352
Copyright © Bayer MaterialScience
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Graphene/ Graphite
Breakthrough in proton barrier films using pore-free graphene oxide: Kumamoto University researchers achieve new milestone in advanced coating technologies September 13th, 2024
NRL discovers two-dimensional waveguides February 16th, 2024
Nanotubes/Buckyballs/Fullerenes/Nanorods/Nanostrings
Tests find no free-standing nanotubes released from tire tread wear September 8th, 2023
Detection of bacteria and viruses with fluorescent nanotubes July 21st, 2023
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||